Endoplasmic reticulum aminopeptidases ERAP1 and 2 are
intracellular
aminopeptidases that trim antigenic precursors and generate antigens
presented by major histocompatibility complex class I (MHC-I) molecules.
They thus modulate the antigenic repertoire and drive the adaptive
immune response. ERAPs are considered as emerging targets for precision
immuno-oncology or for the treatment of autoimmune diseases, in particular
MHC-I-opathies. This perspective covers the structural and biological
characterization of ERAP, their relevance to these diseases and the
ongoing research on small-molecule inhibitors. We describe the chemical
and pharmacological space explored by medicinal chemists to exploit
the potential of these targets given their localization, biological
functions, and family depth. Specific emphasis is put on the binding
mode, potency, selectivity, and physchem properties of inhibitors
featuring diverse scaffolds. The discussion provides valuable insights
for the future development of ERAP inhibitors and analysis of persisting
challenges for the translation for clinical applications.